N,N-dimethyl-4-{[(propan-2-yl)amino]methyl}aniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-dimethyl-4-{[(propan-2-yl)amino]methyl}aniline
• 英文别名: N,N-dimethyl-4-[(propan-2-ylamino)methyl]aniline
• 化学式: C₁₂H₂₀N₂
• mdl: MFCD00114084
• 分子量: 192.3
• InChiKey: NZXPKDJRJFKEIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Acat inhibitors
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0433662A2

  公开（公告）日：1991-06-26

  The invention is novel compounds having acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitory activity of the formula I The invention further comprises a process for the preparation of compounds of the formula I, pharmaceutical compositions containing them and the use of compounds (I) for the preparation of pharmaceutical compositions useful for treating hypercholesterolemia and atherosklerosis.

  本发明是具有式 I 的酰基辅酶 A：胆固醇酰基转移酶（ACAT）抑制活性的新型化合物。 本发明还包括制备式 I 化合物、含有这些化合物的药物组合物以及使用化合物 (I) 制备用于治疗高胆固醇血症和动脉粥样硬化症的药物组合物的工艺。
• Polyene macrolide derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10246478B2

  公开（公告）日：2019-04-02

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

  本发明是以下两性霉素 B 衍生物： 其中各符号在说明中定义。本发明化合物的第 16 位（X）是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。
• Blocking toll-like receptor 9 signaling with small molecule antagonist
  申请人：Council of Scientific & Industrial Research

  公开号：US10662177B2

  公开（公告）日：2020-05-26

  The present invention relates to small molecule 4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defense for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.

  本发明涉及小分子 4-(哌嗪-1-基)喹唑啉-2-氨基化合物，其式(I)有助于抑制某些类毒素受体（TLRs），特别是 TLR9 的信号传导。类毒素受体（TLRs）是进化保守的模式识别受体大家族的成员，是宿主免疫反应识别自我和非自我的关键第一道防线。TLR9的异常激活与不同自身免疫性疾病中的自身反应性炎症有关。本发明描述的式(I)化合物、组合物和方法可用于多种临床应用，包括作为药物制剂和方法用于治疗因TLR9活化而导致的不需要的免疫活动。
• [EN] CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE PYRIDINE À SUBSTITUTION CYANO ET COMPOSÉ DE PYRIMIDINE À SUBSTITUTION CYANO, PROCÉDÉ DE PRÉPARATION CORRESPONDANT ET UTILISATION ASSOCIÉE<br/>[ZH] 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
  申请人：BEIJING SCITECH MQ PHARMACEUTICALS LTD

  公开号：WO2019242689A1

  公开（公告）日：2019-12-26

  提供一种式(I)所示化合物、其异构体、水合物、溶剂化物、其药学上可接受的盐及其前药，其制备方法及其在制备作为激酶抑制剂的药物中的应用。该化合物对FGFR4及突变型FGFR4 V550L等激酶均具有良好的抑制活性。
• POLYENE MACROLIDE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：US20170190729A1

  公开（公告）日：2017-07-06

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.